NASDAQ
76.61USD
+0.05 (+0.07%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
1.6B
P/E
—
EPS
—
Beta
2.84
52W range
9.91-77.2
Day range
76.56–76.68
Open
76.60
Prev close
76.56
Volume
1.4M
Avg volume
682.4K
Dividend
0.00
IPO
2017-04-13
https://www.globenewswire.com/news-release/2026/08/06/3340172/0/en/argenx-Announces-Commencement-of-Tender-Offer-to-Acquire-Forte-Biosciences-Inc.html · 8/6/2026+1.00
https://www.benzinga.com/markets/market-summary/26/07/60702801/crude-oil-falls-sharply-us-durable-goods-orders-increase-0-3-in-june · 7/27/2026+1.00
https://www.globenewswire.com/news-release/2026/07/27/3333257/0/en/argenx-to-Acquire-Forte-Biosciences-Inc-Adding-First-in-Class-anti-CD122-Antibody-FB102-to-its-Immunology-Pipeline.html · 7/27/2026+1.00
https://www.businesswire.com/news/home/20260408582507/en/Forte-Biosciences-Announces-Pricing-of-150-Million-Public-Offering/ · 4/9/2026-0.50
https://www.businesswire.com/news/home/20260209147037/en/Forte-Biosciences-Inc.-to-Present-at-Upcoming-Investor-Meetings/ · 2/9/2026
https://www.defenseworld.net/2025/11/27/forte-biosciences-target-of-unusually-high-options-trading-nasdaqfbrx.html · 11/27/2025-0.20
Forte Biosciences, Inc. is a U.S.-based biopharmaceutical company currently in its clinical development phase. The firm's key initiative involves advancing the FB-102 program, which is designed to tackle a variety of autoimmune conditions, notably vitiligo and alopecia areata. Their main offices are situated in Dallas, Texas.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works